Search results for "alzheimer’s disease"

showing 10 items of 120 documents

Common miRNA Patterns of Alzheimer's Disease and Parkinson's Disease and Their Putative Impact on Commensal Gut Microbiota.

2019

With the rise of Next-Generation-Sequencing (NGS) methods, Micro-RNAs (miRNAs) have achieved an important position in the research landscape and have been found to present valuable diagnostic tools in various diseases such as multiple sclerosis or lung cancer. There is also emerging evidence that miRNAs play an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) or Parkinson’s disease (PD). Apparently, these diseases come along with changes in miRNA expression patterns which led to attempts from researchers to use these small RNA species from several body fluids for a better diagnosis and in order to observe disease progression. Additionally, it…

610 Medical sciencesmicro-RNAsneurodegenerationParkinson’s disease610 Medizingut microbiomeAlzheimer’s diseaselcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroscienceOriginal Researchcrosstalklcsh:RC321-571Frontiers in neuroscience
researchProduct

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.

2019

Abstract Alzheimer’s disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. M…

0301 basic medicineFarmacologiaADAM10DiseaseRM1-950Natural compoundsCleavage (embryo)NeuroprotectionCatechin03 medical and health sciencesADAM10 ProteinAmyloid beta-Protein Precursor0302 clinical medicineAlzheimer DiseaseDisintegrinHumansSenile plaquesPharmacological modulationPharmacologyMetalloproteinaseAmyloid beta-PeptidesbiologyChemistryPlant ExtractsADAM10ProteinsGinkgo bilobaMembrane ProteinsGeneral Medicineα-SecretaseAlzheimer's disease030104 developmental biologyMalaltia d'AlzheimerNeuroprotective Agents030220 oncology & carcinogenesisPharmaceuticalbiology.proteinTherapeutics. PharmacologyAmyloid Precursor Protein SecretasesNeuroscienceAlzheimer’s diseaseProteïnesBiomarkersBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

The FOXP2-Driven Network in Developmental Disorders and Neurodegeneration

2017

The transcription repressor FOXP2 is a crucial player in nervous system evolution and development of humans and songbirds. In order to provide an additional insight into its functional role we compared target gene expression levels between human neuroblastoma cells (SH-SY5Y) stably overexpressing either human FOXP2 cDNA or its orthologues from the common chimpanzee, Rhesus monkey, and marmoset, respectively. Subsequent RNA-seq led to identification of 27 genes with differential regulation under the control of human FOXP2, which were previously reported to have FOXP2-driven and/or songbird song-related expression regulation. Importantly, RT-qPCR and Western blotting indicated differential re…

0301 basic medicineCell signalingCytoskeleton organizationspeechbrainBiologyAxonogenesislcsh:RC321-57103 medical and health sciencesCellular and Molecular NeuroscienceHuntington's diseasemedicineGeneTranscription factorlcsh:Neurosciences. Biological psychiatry. Neuropsychiatryneuronal circuitryOriginal ResearchlanguageNeurodegenerationFOXP2medicine.diseaseschizophrenia030104 developmental biologyParkinson’s diseaseNeuroscienceAlzheimer’s diseaseNeuroscienceHuntington’s diseaseFrontiers in Cellular Neuroscience
researchProduct

Association Between Interleukin-10 Polymorphisms and Alzheimer's Disease: A Systematic Review and Meta-Analysis

2012

UNLABELLED It has been hypothesized that polymorphisms of interleukin (IL)-10 genes affect the risk of developing late onset Alzheimer's disease (AD). However, results of different studies are often inconsistent. Our aim was to investigate by meta-analysis the association of the common polymorphisms comprehensively defining the genetic variability of the IL-10 gene with AD risk. Fifteen studies investigating the association between IL-10 polymorphisms (-1082, -819, -592) and AD were found and analyzed. The model-free approach was applied to meta-analyze these case-control genetic association studies. Available data suggested an association between -1082 polymorphism and AD risk with a margi…

Oncologymedicine.medical_specialtyAlzheimer’s disease IL-10 meta-analysis polymorphismsLower riskPolymorphism Single NucleotideAlzheimer DiseasePolymorphism (computer science)Internal medicineGenotypeHumansMedicineGenetic Predisposition to DiseaseGenetic variabilityGenetic Association StudiesGenetic associationSettore MED/04 - Patologia GeneraleGeneticsbusiness.industryGeneral NeuroscienceHaplotypeGeneral MedicineOdds ratioInterleukin-10Psychiatry and Mental healthClinical PsychologyMeta-analysisGeriatrics and GerontologybusinessJournal of Alzheimer's Disease
researchProduct

No association between the cystatin C gene polymorphism and Alzheimer's disease: a case-control study in an Italian population.

2005

Cystatin C is an amyloidogenic protein found together with beta-amyloid in cerebral arteriolar walls of both patients with Alzheimer's Disease (AD) and conghopilic amyloid angiopathy. Several findings implicate cystatin C in the pathogenesis of vascular diseases. Recent genetic association studies proposed cystatin C gene (CST3) as a susceptibility factor for AD, although other reports did not replicate this finding. We conducted a case-control study including 192 probable AD cases and 192 age- and sex-matched controls to test the association between CST3 and AD. Possible interaction between CST3 and age at onset of AD or apolipoprotein E (APOE) was also examined. No significant differences…

MaleApolipoprotein EGenotypeDiseasePathogenesisApolipoproteins EAlzheimer DiseaseGenotypeHumansGenetic Predisposition to DiseaseCystatin CAllele frequencyAllelesAgedGenetic associationAged 80 and overGeneticsGenomic LibraryPolymorphism GeneticbiologyKeywords: Alzheimer’s disease cystatin C apolipoprotein E case-control study polymorphismGeneral NeuroscienceCase-control studyGeneral MedicineMiddle AgedCystatinsPsychiatry and Mental healthClinical PsychologyItalyCystatin CCase-Control StudiesImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleGeriatrics and Gerontology
researchProduct

Role of TLR Polymorphisms in Aging and Age-Related Diseases

2017

Innate immunity provides the first line of host defense against infection by recognizing and killing microbes, and simultaneously activating an instructive immune response. Toll-like receptors (TLRs) are principal mediators of rapid microbial recognition, and they mainly function by detecting exogenous pathogen-associated molecular patterns. Recognition of their ligands actives signaling ways, which culminate in evocating acute host responses, involved in killing pathogens. Here, we describe the involvement of TLR4 polymorphisms in aging, and particularly in immunosenescence and age-related diseases, suggesting the crucial role of molecules of innate immunity in the pathophysiology of these…

Settore MED/04 - Patologia Generalebusiness.industryAge relatedImmunologySettore MED/05 - Patologia ClinicaMedicineTLR4 • Alzheimer’s disease • Prostate cancer • Diabetes • Atherosclerosis • Aneurysm • Longevitybusiness
researchProduct

Physical activity may not be associated with long-term risk of dementia and Alzheimer's disease.

2020

Background: While it is well established that physical activity is associated with reduced risk of vascular and non-vascular outcomes as well as mortality, evidence on the association between physical activity and dementia is inconsistent. We aimed to assess the associations of physical activity with the risk of dementia and Alzheimer’s disease (AD).Material and methods: We analysed data on 2,394 apparently healthy men with good baseline cognitive function from the prospective population-based Kuopio Ischaemic Heart Disease study. We assessed habits of physical activity at baseline using a 12-month leisure-time physical activity (LTPA) questionnaire. Using Cox regression, we calculated haza…

Malemedicine.medical_specialtyClinical BiochemistryPopulationRegression dilutionphysical activity030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineInterquartile rangeAlzheimer DiseaseInternal medicinemedicinecohort studyDementiaHumans030212 general & internal medicineRisk factoreducationExerciseFinlandAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyOriginal Paperbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle AgedAlzheimer's diseasemedicine.diseaserisk factorDementiabusinessAlzheimer’s diseaseCohort studydementiaEuropean journal of clinical investigation
researchProduct

Alzheimer's disease: amino acid levels and brain metabolic status.

2013

Abstract To study brain free amino acids and their relation with dementia we measured, by high-performance liquid chromatography (HPLC), the concentration of eight free amino acids, amines and related compounds. We used temporal cortex (TC) samples obtained from 13 Alzheimer’s disease (AD) patients and an equal number of agematched controls (AC). The patterns of free amino acids, amines and related compounds showed significant quantitative changes in AD conditions with respect to healthy ones. In Alzheimer patients, lower levels of GABA were found in the TC (-57 %). Amino acids glutamate (Glu), and aspartate (Asp) concentrations, also appeared significantly reduced in the TC of AD patients …

Malemedicine.medical_specialtyDermatologyBiologychemistry.chemical_compoundBrain: Temporal cortexAlzheimer DiseaseSettore BIO/10 - BiochimicaInternal medicinemedicineHumansNeurotransmitterAmino AcidsChromatography High Pressure Liquidgamma-Aminobutyric AcidAgedTemporal cortexchemistry.chemical_classificationMethionineGlutamate receptorBrainGeneral Medicinemedicine.diseaseCystathionine beta synthaseAmino acidAmino acidGlutaminePsychiatry and Mental healthEndocrinologychemistryBiochemistryTemporal cortex; Amino acids; Neurotransmitters; [Keywords Alzheimer’s disease; Brain]biology.proteinFemaleKeywords Alzheimer’s diseaseNeurology (clinical)Alzheimer's diseaseTransmethylationNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Systemic Immune Responses in Alzheimer's Disease: In Vitro Mononuclear Cell Activation and Cytokine Production

2010

To investigate the systemic signs of immune-inflammatory responses in Alzheimer's disease (AD), in the present study we have analyzed blood lymphocyte subsets and the expression of activation markers on peripheral blood mononuclear cells (PBMCs) from AD patients and age-matched healthy controls (HC) activated in vitro by recombinant amyloid-beta peptide (rAbeta42). Our study of AD lymphocyte subpopulations confirms the already described decrease of the absolute number and percentage of B cells when compared to HC lymphocytes, whereas the other subsets are not significantly different in patients and controls. We report the increased expression of the activation marker CD69 and of the chemoki…

MaleEotaxinCCR2ChemokineTime Factorsmedicine.medical_treatmentPeripheral blood mononuclear cellChemokine receptorImmune systemAlzheimer’s disease chemokine cytokine PBMC rAβ42Alzheimer DiseasemedicineHumansLymphocytesIL-2 receptorCells CulturedAgedSettore MED/04 - Patologia GeneraleAged 80 and overAnalysis of VarianceAmyloid beta-Peptidesbiologybusiness.industryGeneral NeuroscienceGeneral MedicineMiddle AgedFlow CytometryPeptide FragmentsPsychiatry and Mental healthClinical PsychologyCytokineGene Expression RegulationCase-Control StudiesImmunologyLeukocytes Mononuclearbiology.proteinCytokinesFemaleGeriatrics and GerontologybusinessJournal of Alzheimer's Disease
researchProduct

Alzheimer’s disease and infections, where we stand and where we go

2014

Editorial Alzheimer’s disease (AD) is a progressive neurological disorder, which represents the most common form of dementia, one of the major causes of disability in later life. Age is the greatest risk factor for AD, which typically affects people aged 65 years and over, with an age-standardised prevalence of 4.4 [1]. However, AD is not a normal part of ageing and advanced age alone does not justify the disease. Several pathways have been implicated in AD pathophysiology, the most described is the neurodegenerative one, which lead to the brain accumulation of beta-amyloid and neurofibrillary tangles, aggregations of hyperphosphorylated tau protein, macroscopically resulting in brain atrop…

AgingTraumatic brain injuryImmunologyTau proteinperiodontal diseaseDiseaseInfectionsBioinformaticsAtrophyAlzheimer'MedicineDementiaRisk factorAlzheimer's; infections; herpes viruses; periodontal disease; infectionInflammationSettore MED/04 - Patologia Generalebiologybusiness.industryVascular diseaseHerpes virusesOdds ratiomedicine.diseaseinfectionAgeingEditorialImmunologybiology.proteinherpes viruseSettore MED/26 - NeurologiabusinessAlzheimer’s diseaseImmunity & Ageing
researchProduct